Amneal Historical Income Statement
| AMRX Stock | USD 8.35 0.10 1.21% |
Historical analysis of Amneal Pharmaceuticals, income statement accounts such as Interest Expense of 119.8 M, Selling General Administrative of 281.2 M or Total Revenue of 1.7 B can show how well Amneal Pharmaceuticals, Class performed in making a profits. Evaluating Amneal Pharmaceuticals, income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Amneal Pharmaceuticals,'s future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Amneal Pharmaceuticals, latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Amneal Pharmaceuticals, is a good buy for the upcoming year.
Amneal |
About Amneal Income Statement Analysis
Amneal Pharmaceuticals, Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Amneal Pharmaceuticals, shareholders. The income statement also shows Amneal investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Amneal Pharmaceuticals, Income Statement Chart
Add Fundamental
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Total Revenue
Total revenue comprises all receipts Amneal Pharmaceuticals, generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Amneal Pharmaceuticals, Class minus its cost of goods sold. It is profit before Amneal Pharmaceuticals, operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Amneal Pharmaceuticals,. It is also known as Amneal Pharmaceuticals, overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Most accounts from Amneal Pharmaceuticals,'s income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Amneal Pharmaceuticals, current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amneal Pharmaceuticals, Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Amneal Pharmaceuticals,'s EBIT is fairly stable compared to the past year. Research Development is likely to rise to about 200.3 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 154.9 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 769.0M | 784.7M | 820.6M | 675.9M | Total Revenue | 2.1B | 2.2B | 2.4B | 1.7B |
Amneal Pharmaceuticals, income statement Correlations
Click cells to compare fundamentals
Amneal Pharmaceuticals, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Amneal Pharmaceuticals, income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 207.2M | 235.4M | 233.4M | 240.2M | 229.4M | 154.9M | |
| Interest Expense | 168.2M | 146.0M | 136.3M | 158.4M | 210.6M | 119.8M | |
| Selling General Administrative | 289.6M | 326.7M | 365.7M | 400.4M | 429.7M | 281.2M | |
| Total Revenue | 1.6B | 2.0B | 2.1B | 2.2B | 2.4B | 1.7B | |
| Gross Profit | 353.0M | 628.4M | 769.0M | 784.7M | 820.6M | 675.9M | |
| Other Operating Expenses | 1.8B | 1.9B | 1.9B | 2.0B | 2.2B | 1.5B | |
| Operating Income | (137.4M) | 91.2M | 209.2M | 206.5M | 204.4M | 122.7M | |
| Net Income From Continuing Ops | (603.6M) | 68.6M | 20.2M | (254.8M) | (48.7M) | (46.3M) | |
| Ebit | (137.4M) | 145.7M | 216.6M | (89.8M) | 271.4M | 285.0M | |
| Research Development | 202.3M | 190.6M | 209.6M | 200.0M | 167.8M | 200.3M | |
| Ebitda | 69.8M | 381.0M | 450.0M | 150.4M | 500.8M | 334.5M | |
| Cost Of Revenue | 1.3B | 1.4B | 1.3B | 1.4B | 1.6B | 1.0B | |
| Total Operating Expenses | 491.9M | 517.3M | 575.1M | 595.8M | 616.2M | 481.7M | |
| Income Before Tax | (220.2M) | (35.8M) | 31.4M | (248.1M) | (40.3M) | (38.3M) | |
| Total Other Income Expense Net | (82.8M) | (126.9M) | (121.4M) | (153.2M) | (244.6M) | (232.4M) | |
| Net Income Applicable To Common Shares | (361.9M) | 91.1M | 10.6M | (130.0M) | (117.0M) | (111.1M) | |
| Net Income | (603.6M) | 68.6M | 20.2M | (254.8M) | (84.0M) | (79.8M) | |
| Income Tax Expense | 383.3M | (104.4M) | 11.2M | 6.7M | 8.5M | 8.0M | |
| Minority Interest | 114.8M | (22.5M) | 9.5M | (125.2M) | (35.3M) | (33.5M) | |
| Tax Provision | 383.3M | (104.4M) | 11.2M | 6.7M | 8.5M | 8.0M | |
| Net Interest Income | (168.2M) | (146.0M) | (136.3M) | (158.7M) | (251.4M) | (238.9M) | |
| Reconciled Depreciation | 207.2M | 235.4M | 233.4M | 240.2M | 229.4M | 208.8M | |
| Non Recurring | 107.6M | 21.6M | 35.3M | 288.7M | 332.0M | 348.6M | |
| Non Operating Income Net Other | 196.6M | 19.1M | 15.0M | 5.2M | 4.7M | 4.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.